Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD

This study has been completed.
Sponsor:
Information provided by:
Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier:
NCT00629044
First received: February 25, 2008
Last updated: March 25, 2011
Last verified: August 2009
History of Changes
  Purpose

The aim of this study is to assess the implicitement of the cholesterol 24 S hydroxylase gene and the 24 S hydroxycholesterol in glaucoma and in age related macular degeneration.


Condition Intervention
Glaucoma
 Biological: Assessing the blood level of cholesterol 24 S Hydroxylase
Biological: Assessing the blood level of cholesterol 24 S hydroxylase
Biological: assessing the blood level of cholesterol 24 S hydroxylase

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol Glaucoma
U.S. FDA Resources

Further study details as provided by Centre Hospitalier Universitaire Dijon:

Primary Outcome Measures:
  • To know if cholesterol 24 S hydroxylase and 24 hydroxycholesterol are involve in Glaucoma and AMD [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 320
Study Start Date: November 2007
Study Completion Date: January 2011
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: G Biological: Assessing the blood level of cholesterol 24 S Hydroxylase
Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
Active Comparator: AMD Biological: Assessing the blood level of cholesterol 24 S hydroxylase
Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
Active Comparator: Healthy subjects Biological: assessing the blood level of cholesterol 24 S hydroxylase
Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects

  Eligibility
Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patient with Glaucoma
  • Patient with AMD
  • Healthy patient

Exclusion Criteria:

  • All patients who use any treatment in order to maintain in normal value their blood cholesterol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00629044

Locations
France
Ophthalmology Unit CHU Dijon
Dijon, Burgundy, France, 21000
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
Investigators
Principal Investigator: Catherine Creuzot-Gracher, MD, PhD CHU Dijon
  More Information

Publications:

Responsible Party: Professor Catherine Creuzot-Garcher, CHU Dijon
ClinicalTrials.gov Identifier: NCT00629044     History of Changes
Other Study ID Numbers: PHRC IR 2006
Study First Received: February 25, 2008
Last Updated: March 25, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

ClinicalTrials.gov processed this record on March 03, 2015